Metformin, an insulin‐sensitizing drug that is the first‐line treatment for type 2 diabetes mellitus (T2DM), may have a potential neuroprotective impact by up‐regulating the production of FGF21, which may prevent the onset of neurodegenerative diseases including MS. The gene discussed is INS; the disease is myeloid sarcoma.